Overview

A Study of HTD1801 in Healthy Subjects

Status:
Completed
Trial end date:
2017-10-03
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.
Phase:
Phase 1
Details
Lead Sponsor:
HighTide Biopharma Pty Ltd